lobucavir

lobucavir

Virology A nucleoside analogue broad-spectrum antiviral for HBV, HS-1, HS-2, herpes zoster. See Antiviral, Nucleoside analogue.
References in periodicals archive ?
lamivudine, lobucavir, famciclovir, adefovir) to inhibit polymerase activity.
10 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) announced today that preliminary observations in its lifetime rodent toxicology studies of lobucavir have revealed a possible drug-related increase in tumor occurrence.
CMD's principal pharmaceutical clients include Pfizer Pharmaceutical (for whom CMD manages programs for Viagra, Trovan and Zoloft, among other products), Bristol-Meyers Squibb Company (for its Zerit, Videx, Lobucavir, Glucophage and other medications), Genetics Institute Biomatrix and Proctor & Gamble Pharmaceuticals.
Among them are: lobucavir, a broad spectrum antiviral agent now in Phase III clinical development; an HIV protease inhibitor about to enter Phase II; a nucleoside analog in Phase II for the treatment of hepatitis B; a new azole antifungal compound in Phase II; and a promising new broad-spectrum des-fluoroquinolone in preclinical development.
Studies with Lobucavir in Herpes Viruses Underway Worldwide -
Lobucavir is in late stage development for treatment of hepatitis B (HBV) and herpes infections.
Lobucavir is a broad-spectrum nucleoside analogue antiviral with activity against hepatitis B and herpes viruses.
In each study, lobucavir will be dosed orally and once a day.
Results from an early Phase II study with lobucavir in 95 patients was presented to physicians this week at the annual meeting of the American Association for the Study of Liver Diseases.
Lobucavir, a broad-spectrum oral antiviral agent, particularly
This compound, following lobucavir, gives Bristol-Myers
Development efforts in hepatitis underway at the company include investigation of two compounds: lobucavir for hepatitis B and cytomegalovirus now in Phase II trials, and BMS-200475 for hepatitis B in Phase I trials.